Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer
Authors:
- Klara HammarströmKHKlara Hammarström
- Luís NunesLNLuís Nunes
- Lucy MathotLMLucy Mathot
- Artur MezheyeuskiAMArtur Mezheyeuski
- Emma LundinELEmma Lundin
- Nafsika Korsavidou HultNHNafsika Korsavidou Hult
- Israa ImamIIIsraa Imam
- Emerik OsterlundEOEmerik Osterlund
- Tobias SjöblomTSTobias Sjöblom
- Bengt GlimeliusBengt Glimelius
Open Access
- 20 February 2024
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 155 (1) , 40-53
Abstract
Rectal cancer poses challenges in preoperative treatment response, with up to 30% achieving a complete response (CR). Personalized treatment relies on accurate identification of responders at diagnosis. This study aimed to unravel CR determinants, overall survival (OS), and time to recurrence (TTR) using clinical and targeted sequencing data. Analyzing 402 patients undergoing preoperative treatment, tumor stage, size, and treatment emerged as robust response predictors. CR rates were higher in smaller, early‐stage, and intensively treated tumors. Targeted sequencing analyzed 216 cases, while 120 patients provided hotspot mutation data. KRAS mutation dramatically reduced CR odds by over 50% (odds ratio [OR] = 0.3 in the targeted sequencing and OR = 0.4 hotspot cohorts, respectively). In contrast, SMAD4 and SYNE1 mutations were associated with higher CR rates (OR = 6.0 and 6.8, respectively). Favorable OS was linked to younger age, CR, and low baseline carcinoembryonic antigen levels. Notably, CR and an APC mutation increased TTR, while a BRAF mutation negatively affected TTR. Beyond tumor burden, SMAD4 and SYNE1 mutations significantly influenced CR. KRAS mutations independently correlated with radiotherapy resistance, and BRAF mutations heightened recurrence risk. Intriguingly, non‐responding tumors with initially small sizes carried a higher risk of recurrence. The findings, even if limited in addition to the imperfect clinical factors, offer insights into rectal cancer treatment response, guiding personalized therapeutic strategies. By uncovering factors impacting CR, OS, and TTR, this study underscores the importance of tailored approaches for rectal cancer patients. These findings, based on extensive analysis and mutation data, pave the way for personalized interventions, optimizing outcomes in the challenges of rectal cancer preoperative treatment.Keywords
Funding Information
- Cancerfonden (190382PJ01H)
This publication has 25 references indexed in Scilit:
- Watch-and-wait strategy in rectal cancer: Is there a tumour size limit? Results from two pooled prospective studiesRadiotherapy and Oncology, 2021
- Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancerJournal of Surgical Oncology, 2020
- Stage distribution utilizing magnetic resonance imaging in an unselected population of primary rectal cancersEuropean Journal of Surgical Oncology, 2018
- Two countries – Two treatment strategies for rectal cancerRadiotherapy and Oncology, 2016
- A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APCNature Communications, 2016
- HaloPlex Targeted Resequencing for Mutation Detection in Clinical Formalin-Fixed, Paraffin-Embedded Tumor SamplesThe Journal of Molecular Diagnostics, 2015
- Novel Single-Nucleotide Polymorphism Markers Predictive of Pathologic Response to Preoperative Chemoradiation Therapy in Rectal Cancer PatientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Higher prevalence of sexual dysfunction in colon and rectal cancer survivors compared with the normative population: A population-based studyEuropean Journal of Cancer, 2012
- Performance comparison of benchtop high-throughput sequencing platformsNature Biotechnology, 2012
- Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancerBritish Journal of Surgery, 2012